Información sobre riesgo, prevención, detección, síntomas, diagnosis, tratamiento y apoyo para el cáncer.
Información sobre el tratamiento del cáncer incluyendo quirúrgica, quimioterapia, radioterapia, estudios clínicos, terapia con protón, medicina complementaria avanzadas.
OncoLink se complace en ofrecer una amplia lista de lista completa de los agentes quimioterapéuticos más comúnmente usados??. Esta guía de referencia incluye información sobre la forma en que cada fármaco se administra, cómo funcionan, y los pacientes los efectos secundarios comunes pueden experimentar.
Maneras que los pacientes de cáncer y las personas que le cuidan puedan enfrentar el cáncer, los efectos secundarios, nutrición, cuestiones en general sobre el apoyo para el cáncer, duelo/decisiones sobre el termino de vida, y experiencias compartidas por sobrevivientes.
National Cancer Institute®
Ultima Vez Modificado: 1 de marzo del 2002
UI - 11697655
AU - Glaser SL; Clarke CA; Stearns CB; Dorfman RF
TI - Age variation in Hodgkin's disease risk factors in older women: evidence from a population-based case-control study.
SO - Leuk Lymphoma 2001 Sep-Oct;42(5):997-1004
AD - Northern California Cancer Center, Union City 94587, USA.
Hodgkin's disease (HD), which affects all age groups, has been associated with childhood social class, particularly among adults under age 40. Little is known about social class risk factors in older adults, and the few existing studies have conflicting findings. As part of a population-based case-control study of HD in women, we examined social class risk factors by diagnostic age groups (45-54 years and 55-79 years) corresponding to incidence patterns and by histologic subtypes based on a uniform pathologic review. Among women ages 45-54, cases were more likely to be Catholic, to have lower income and to be taller than controls. Among women ages 55-79, cases tended to have come from small or large childhood households, lived in single-family childhood housing, and had a single rather than shared bedroom at age 11. For the nodular sclerosis (NS) histologic subtype, similar age differences in risk factors were apparent. Comparisons between the NS and non-NS subtypes in women ages 55-79 identified some common risk factors (single-family childhood home, single bedroom at age 11) but others specific to one subtype (childhood household size, adult height for NS; lower maternal education for non-NS). Thus, some social class associations with HD differed between middle-aged and older women, as well as between these groups and younger adults, while others were shared across age groups. Risk also was associated with both higher and lower childhood social class in middle-aged and older women, in contrast with previous findings. None of these patterns was explained entirely by histologic subtype but may reflect age and histology subtype variation in the HD-EBV association.
UI - 11554231
AU - Moschovi M; Psychou F; Menegas D; Tsangaris GT; Tzortzatou-Stathopoulou
TI - F; Nikolaidou P Hodgkin's disease in a child with sickle cell disease treated with hydroxyurea.
SO - Pediatr Hematol Oncol 2001 Sep;18(6):371-6
AD - Oncology Unit, First Department of Pediatrics, University of Athens, Agia Sophia Children's Hospital, Athens, 11527 Greece.
Hydroxyurea (HU) is an oral drug that ameliorates the clinical course of sickle cell anemia by increasing the levels of fetal hemoglobin and decreasing the adhesion of red cells to endothelium. Although HU has minimal short-term toxicity, few data are available about the long-term safety and the potential risk for carcinogenesis or leukemogenesis. An 8-year-old child with sickle cell/beta 0-thalassemia who received HU treatment for painful crises is described. Six months after the initiation of the HU treatment he developed Hodgkin's disease, lymphocyte predominance subtype. Chemotherapy induced a complete remission. After discontinuation of chemotherapy the painful crises recurred and bone marrow transplantation was decided at the age of 12 years. Two years after the bone marrow transplantation, the child is in complete remission without painful crises. Although the authors suggest that the development of Hodgkin's disease is a coexisting event, questions arise about the safety of HU treatment in childhood.
UI - 11554236
AU - Ragusa R; Russo S; Villari L; Schiliro G
TI - Hodgkin's disease as a second malignant neoplasm in childhood: report of a case and review of the literature.
SO - Pediatr Hematol Oncol 2001 Sep;18(6):407-14
AD - Department of Pediatric Hematology and Oncology, University of Catania, Via Santa Sofia, 78 95123, Catania, Italy.
There is a known association between lymphoid malignancy and Hodgkin's disease (HD), but the development of HD in children who have been treated for leukemia or lymphoma is very uncommon. Hodgkin's disease is, after retinoblastoma, the most common primary tumor that is associated with development of second malignant neoplasm. For reasons that remain to be determined, HD is very rare as a second malignancy [1, 2, 3]. We report the case of a eight-year-old girl who developed HD 6 years after treatment for common acute lymphoblastic leukemia (ALL). This case prompted us to review the published literature for cases of secondary HD in childhood. Our experience suggests that we should follow strictly our patients with ALL and be ready to intervene with invasive diagnostic procedures at the least suspicion of a second or recurrent neoplasm. The most frequent causes of second tumors are radiotherapy, genetic susceptibility and prior treatment with certain chemotherapeutic agents, such as nitrogen mustards. It is likely that any type of immunodeficiency, even without symptoms, might play a role in the development of second tumors in childhood.
UI - 11843811
AU - Naumann R; Vaic A; Beuthien-Baumann B; Bredow J; Kropp J; Kittner T;
TI - Franke WG; Ehninger G Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma.
SO - Br J Haematol 2001 Dec;115(4):793-800
AD - Department of Internal Medicine I, University Hospital Carl Gustav Carus at the Dresden University of Technology, Fetscherstrasse 74, D-01307 Dresden, Germany. email@example.com
The prognostic value of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in the assessment of post-treatment residual masses in patients with Hodgkin's disease (HD) or non-Hodgkin's lymphomas (NHL) was evaluated. We prospectively studied 58 patients with HD (n = 43) or NHL (n = 15) who had post-therapeutic complete remission with residual masses (CRu) indicated by computerized tomography. Analysis of 62 residual locations by FDG-PET was performed separately for HD and NHL. Patients with a PET-positive residual mass [standardized uptake value (SUV) > 3] had a recurrence rate of 62.5% (5/8 patients), whereas patients with PET-negative residual mass (SUV < or =3.0) showed a recurrence rate of 4% (2/50 patients, P = 0.004). A positive FDG-PET study correlated with a significantly poorer progression-free survival (P < 0.00001). No recurrence occurred in any of the 39 HD patients with a negative PET scan (negative predictive value, 100%). Four out of four NHL patients with a positive PET study relapsed (positive predictive value, 100%). In conclusion, FDG-PET is a suitable non-invasive method with a high degree of accuracy in the prediction of early recurrence in lymphoma patients with CRu.
UI - 11805358
AU - Thavaraj V; Kumar R; Arya LS
TI - Familial Hodgkin's disease in two siblings.
SO - Indian Pediatr 2002 Jan;39(1):79-83
AD - Department of Pediatrics and Institute of Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi 110 029, India. firstname.lastname@example.org
UI - 11857394
AU - Glaser SL; Clarke CA; Nugent RA; Stearns CB; Dorfman RF
TI - Social class and risk of Hodgkin's disease in young-adult women in 1988-94.
SO - Int J Cancer 2002 Mar 1;98(1):110-7
AD - Northern California Cancer Center, Union City, CA 94587, USA. email@example.com
Hodgkin's disease (HD) risk in young adults has been associated with higher childhood social class. Although recent decades have witnessed increases in both young-adult HD incidence rates and the socioeconomic affluence reported to influence risk, social class risk factors have not been reexamined. For 204 cases and 254 controls aged 19-44 years from a population-based case-control study of HD diagnosed in 1988-94 in San Francisco area females, we evaluated social class predictors of HD overall and for subgroups defined by age and by ethnicity. HD was associated weakly with a few childhood social class markers but more strongly with combinations of these variables. Risk was higher for women with family-owned than rented childhood homes; for US-born women with single vs. shared bedrooms at age 11; and for women with 2+ births who were from smaller than larger childhood households. These patterns differed by age, with risk appearing to increase over the young-adult years for some factors and to decrease for others. In whites, risk was additionally associated with having a single childhood bedroom in larger households, and with tall adult height in women from smaller childhood households. In nonwhites, risk was higher for single bedrooms at age 11 in smaller childhood households, taller height and higher maternal education. Most study findings support the hypothesis that HD development in young adults follows protection from early exposure to other children. Variation in risk by age suggests differing etiologies across young adulthood, or the importance of birth cohort-appropriate social-class measures. Negative findings for previously reported risk factors may reflect their insufficient heterogeneity of exposure or their failure to measure cohort-relevant exposures in this population. Copyright 2001 Wiley-Liss, Inc.
UI - 11852730
AU - Basic-Jukic N; Basic-Koretic M; Radman I; Labar B
TI - Reed-Sternberg cells in the pathogenesis of Hodgkin's disease.
SO - Acta Med Croatica 2001;55(3):115-21
AD - Department of Medicine, Zagreb University Hospital Center, Kispaticeva 12, 10000 Zagreb, Croatia.
Hodgkin/Reed Stemberg (HRS) cells mediate the classical features of Hodgkin's disease. However, because of their rarity in tumor tissue, little is known about their origin and function. Recent advances in biotechnology, including the single cell manipulation, enabled the insight into the biology of HRS cell. It has been demonstrated that in the great majority of cases they are of germinal center B cell origin, with highly developed interactive network with adjacent cells via expression of cell adhesion molecules, tumor necrosis factor receptor superfamily, and elaboration of different cytokines.
UI - 11815733
AU - Skinnider BF; Kapp U; Mak TW
TI - Interleukin 13: a growth factor in hodgkin lymphoma.
SO - Int Arch Allergy Immunol 2001 Dec;126(4):267-76
AD - Amgen Institute, Ontario Cancer Institute and the Departments of Medical Biophysics and Immunology, University of Toronto, Toronto, Canada.
Classical Hodgkin lymphoma (cHL) is a malignant disorder of lymph nodes with distinctive clinical and pathologic features. These features are thought to be primarily due to the abnormal production of multiple cytokines by the malignant cell population of HL, the Reed-Sternberg (RS) cells. We have previously demonstrated that interleukin (IL)-13 expression is a common feature of HL and have studied its role as an autocrine growth factor for RS cells. IL-13 and IL-13R(alpha)1, the IL-13-specific receptor chain, are frequently expressed by HL-derived cell lines and by RS cells from biopsy material of tissues involved by HL. Neutralization of IL-13 in cultures of the HL-derived cell lines HDLM-2 and L-1236 leads to a dose-dependent inhibition of proliferation, and is associated with increased apoptosis in L-1236 cells. Signal transducer and activator of transcription (STAT) 6 is an important mediator of IL-13 signaling. STAT6 is constitutively activated in HL cell lines due to autocrine secretion of IL-13. STAT6 is also phosphorylated (P-STAT6) in RS cells from many primary HL samples, supporting the hypothesis that IL-13 signaling occurs in these malignant cells in vivo. Coexpression of IL-13, IL-13R(alpha)1 and P-STAT6 is uncommon in non-Hodgkin lymphomas. Following a description of the clinical and pathologic features of HL, this review will discuss the function of IL-13 as an autocrine growth factor for RS cells in HL and its potential role in mediating other features of this disease. Copyright 2002 S. Karger AG, Basel
UI - 11872075
AU - Vassilakopoulos TP; Angelopoulou MK; Siakantaris MP; Kontopidou FN;
TI - Dimopoulou MN; Barbounis A; Grigorakis V; Karkantaris C; Anargyrou K; Chatziioannou M; Rombos J; Boussiotis VA; Vaiopoulos G; Kittas C; Pangalis GA Prognostic factors in advanced stage Hodgkin's lymphoma: the significance of the number of involved anatomic sites.
SO - Eur J Haematol 2001 Nov-Dec;67(5-6):279-88
AD - Hematology Section, First Department of Internal Medicine, National and Kapodistrian University, School of Medicine, Laikon General Hospital, Athens, Greece.
BACKGROUND: Advanced Hodgkin's lymphoma (HL) is curable by conventional chemotherapy in 60--70% of patients. The pretreatment identification of a sizeable subgroup of patients with sufficiently low failure-free survival (FFS) to be eligible for investigational treatment is necessary. OBJECTIVES: To determine the prognostic significance of the number of involved sites (NIS) in patients with advanced HL and its relationship to the International Prognostic Score (IPS). METHODS: A retrospective review of patients with advanced HL, defined as Ann Arbor stage (AAS) IB, IIB, III or IV, treated with anthracycline-based regimens. The end-point was FFS. RESULTS: We identified 277 patients with a median age of 32 yr (14--78), 57% of whom were males. AAS was I in 4% of patients, II in 29%, III in 38% and IV in 29%. B-symptoms were recorded in 81%. Most patients had nodular sclerosis (64%) and mixed cellularity (26%) histology. IPS was greater-than-or-equals 3 in 44% of 242 evaluable patients. The NIS was greater-than-or-equals 5 in 32% of the patients and 20% of all patients had both greater-than-or-equals 5 involved sites and IPS greater-than-or-equals 3. The 10-yr FFS was 67%, being 76% vs. 50% for patients with less-than-or-equals 4 vs. greater-than-or-equals 5 involved sites (P < 0.0001). The NIS (greater-than-or-equal 5), AAS IV and anemia were independent predictors of FFS in multivariate analysis. The NIS remained significant along with IPS, when the latter was included in the analysis. Patients with greater-than-or-equals 5 involved sites and IPS greater-than-or-equals 3 had 10-yr FFS overall, and relapse-free survival of 41%, 45% and 49%, respectively. CONCLUSIONS: The NIS was associated with FFS in advanced HL, was independent of IPS, and led to the identification of a sizeable subgroup of patients with 10-yr FFS of approximately 40%. This factor should be evaluated during the development of prognostic systems.
UI - 11848545
AU - Yang CC; Sun SS; Lin CC; Kao CH; Lee CC
TI - Comparison of technetium-99m tetrofosmin and gallium-67 citrate scintigraphy for detecting malignant lymphoma.
SO - Anticancer Res 2001 Sep-Oct;21(5):3695-8
AD - Department of Urology, China Medical College Hospital, Taichung, Taiwan.
The aim of this study was to compare the value of technetium-99m tetrofosmin (Tc-TF) scintigraphy with that of gallium-67 citrate (Ga-67) scintigraphy for detecting malignant lymphoma. In this study, 50 patients with malignant lymphoma underwent Tc-TF and Ga-67 scintigraphy before receiving any therapy. Tc-TF scintigraphy detected malignant lymphoma in 44 (88%) patients, but was false-negative in 4 cases of infradiaphragmatic malignant lymphoma and in 2 cases of malignant lymphoma with chemotherapy resistance. Ga-67 scintigraphy detected malignant lymphoma in 45 (90%) patients, but was false-negative in 3 cases of low-grade non-Hodgkin's lymphoma and in 2 cases of malignant lymphoma with bone marrow involvement. There was no significant difference in sensitivity between Tc-TF and Ga scintigraphy. However, a combination of Tc-TF and Ga-67 scintigraphy detected malignant lymphoma in all 50 patients (100%). We conclude that it is necessary to combine Tc-TF and Ga-67 scintigraphy to accurately detect malignant lymphoma.
UI - 11602997
AU - Glatstein E
TI - As good as it gets--training with Henry Kaplan and Saul Rosenberg during the Stanford studies on Hodgkin's disease and lymphoma.
SO - Cancer Biother Radiopharm 2001 Aug;16(4):269-73
AD - Department of Radiation Oncology, University of Pennsylvania Health System, 3400 Spruce Street, Philadelphia, PA 19104-4283, USA. firstname.lastname@example.org
The Stanford team of Drs. Henry S. Kaplan and Saul A. Rosenberg churned out an extensive amount of clinical research on the evaluation and treatment of Hodgkin's disease and other lymphomas throughout the 1960's, 70's and 80's. After Dr. Kaplan's death in 1983, Dr. Rosenberg continued clinical research in this area. A training experience under these physicians was both exhilarating and productive, as the discipline with which Drs. Kaplan and Rosenberg approached patients actually eclipsed the individual studies which were carried out. The overall product of their efforts, in conjunction with that of other investigators throughout the world, changed the mindset of physicians to approaching these patients with curative intent, rather than traditional palliation which had been the general policy up to the late 1950's. Today the vast majority of Hodgkin's patients who are treated get cured, although there is still some room for further improvement. The strong character traits of Drs. Kaplan and Rosenberg left lasting impressions, not only on other staff, but most especially on the young trainees who learned to accept and appreciate their efforts at excellence. Their method of approach and the gains achieved by it became the paradigm for the study of other malignant diseases.
UI - 11830608
AU - Travis LB; Gospodarowicz M; Curtis RE; Clarke EA; Andersson M; Glimelius
TI - B; Joensuu T; Lynch CF; van Leeuwen FE; Holowaty E; Storm H; Glimelius I; Pukkala E; Stovall M; Fraumeni JF Jr; Boice JD Jr; Gilbert E Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease.
SO - J Natl Cancer Inst 2002 Feb 6;94(3):182-92
AD - Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20892, USA. email@example.com
BACKGROUND: Lung cancer is a frequent cause of death in patients cured of Hodgkin's disease, but the contributions of chemotherapy, radiotherapy, and smoking are not well described. We quantified the risk of treatment-associated lung cancer, taking into account tobacco use. METHODS: Within a population-based cohort of 19 046 Hodgkin's disease patients (diagnosed from 1965 through 1994), a case-control study of lung cancer was conducted. The cumulative amount of cytotoxic drugs, the radiation dose to the specific location in the lung where cancer developed, and tobacco use were compared for 222 patients who developed lung cancer and for 444 matched control patients. All statistical tests were two-sided. RESULTS: Treatment with alkylating agents without radiotherapy was associated with increased lung cancer risk (relative risk [RR] = 4.2; 95% confidence interval [CI] = 2.1 to 8.8), as was radiation dose of 5 Gy or more without alkylating agents (RR = 5.9; 95% CI = 2.7 to 13.5). Risk increased with both increasing number of cycles of alkylating agents and increasing radiation dose (P for trend <.001). Among patients treated with mechlorethamine, vincristine, procarbazine, and prednisone (MOPP), risk increased with cumulative amounts of mechlorethamine and procarbazine (P<.001) when evaluated separately. Statistically significantly elevated risks of lung cancer were apparent within 1-4 years after treatment with alkylating agents, whereas excess risk after radiotherapy began 5 years after treatment and persisted for more than 20 years. Risk after treatment with alkylating agents and radiotherapy together was as expected if individual excess risks were summed. Tobacco use increased lung cancer risk more than 20-fold; risks from smoking appeared to multiply risks from treatment. CONCLUSIONS: Past treatments with alkylating agents and radiation therapy for Hodgkin's disease were associated with an increased risk of lung cancer in a dose-dependent and additive fashion. The precise risk estimates, however, should be interpreted cautiously, given the possible residual and enhancing effects of tobacco.
UI - 11786576
AU - Ferme C; Mounier N; Divine M; Brice P; Stamatoullas A; Reman O; Voillat
TI - L; Jaubert J; Lederlin P; Colin P; Berger F; Salles G Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial.
SO - J Clin Oncol 2002 Jan 15;20(2):467-75
AD - Groupe d'Etudes des Lymphomes de l'Adulte, Hopital Saint-Louis, Paris, France. firstname.lastname@example.org
PURPOSE: To evaluate prospectively the feasibility and efficacy of early intensive therapy, including intensified cytoreductive chemotherapy (CT) and high-dose CT (HDCT) followed by autologous stem-cell transplantation (ASCT), in patients with advanced Hodgkin's disease (HD) who failed to respond completely or relapsed after initial treatment. PATIENTS AND METHODS: Among 533 eligible patients with newly diagnosed stage IIIB-IV HD enrolled in the H89 trial, all 157 patients with induction failure (IF) (n = 67), partial response (PR) of less than 75% (n = 22), or relapse (n = 68) were included in this study. Planned salvage therapy included mitoguazone, ifosfamide, vinorelbine, and etoposide monthly for two to three cycles followed by high-dose carmustine, etoposide, cytarabine, and melphalan with ASCT. RESULTS: With a median follow-up of 50 months, the 5-year survival estimates were 30%, 72%, and 76% for the IF, PR, and relapse groups, respectively (P =.0001), 71% for the 101 patients given HDCT, and 32% for the 48 patients treated without HDCT (P =.0001). Multivariate analysis using time-dependent Cox model indicated that B symptoms at progression, salvage without HDCT, and chemoresistant disease before HDCT were significantly associated with shorter overall survival. CONCLUSION: Early intensive therapy improves the outcomes of patients with advanced HD who failed to respond completely to initial treatment and those who relapsed with adverse prognostic factors. However, for patients with IF and chemoresistant disease, this approach remains unsatisfactory.
UI - 11786577
AU - Sieber M; Tesch H; Pfistner B; Rueffer U; Lathan B; Brosteanu O; Paulus
TI - U; Koch T; Pfreundschuh M; Loeffler M; Engert A; Josting A; Wolf J; Hasenclever D; Franklin J; Duehmke E; Georgii A; Schalk KP; Kirchner H; Doelken G; Munker R; Koch P; Herrmann R; Greil R; Anselmo AP; Diehl V Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5.
SO - J Clin Oncol 2002 Jan 15;20(2):476-84
AD - German Hodgkin's Lymphoma Study Group, Cologne, Germany. email@example.com
PURPOSE: To investigate whether treatment results in intermediate-stage Hodgkin's lymphoma can be improved by rapid application of non-cross-resistant drugs, the 10-drug regimen cyclophosphamide, vincristine, procarbazine, and prednisone (COPP), doxorubicin, bleomycin, and vinblastine (ABV), and ifosfamide, methotrexate, etoposide, and prednisone (IMEP), repeated every 6 weeks, was compared with conventional alternating COPP/doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) administered every 8 weeks. PATIENTS AND METHODS: Hodgkin's lymphoma with at least one risk factor (massive mediastinal tumor, massive spleen involvement, extranodal disease, elevated ESR, or more than two lymph node areas involved) and all patients in stage IIIA Hodgkin's lymphoma were randomized to receive two cycles of COPP/ABVD or COPP/ABV/IMEP followed by extended-field radiotherapy. RESULTS: Both regimens produced similar rates for treatment responses (complete remission, 93% v 94%), freedom from treatment failure (80% v 79%), and overall survival (88% for both regimens) at a median follow-up time of 7 years. Most serious toxicities during chemotherapy were similar in both regimens. However, World Health Organization grade 3 and 4 leukocytopenia occurred significantly more frequently in the COPP/ABV/IMEP arm (53% v 44% of patients; P =.010). There were no differences in the number of serious infections and toxic deaths during therapy. The number of second malignancies was also the same in both arms (22 each). CONCLUSION: Alternating COPP/ABVD and rapid alternating COPP/ABV/IMEP in combination with extended-field radiotherapy are equally effective in intermediate-stage Hodgkin's lymphoma and produce excellent long-term treatment results.
UI - 11839579
AU - Aldinucci D; Poletto D; Gloghini A; Nanni P; Degan M; Perin T; Ceolin P;
TI - Rossi FM; Gattei V; Carbone A; Pinto A Expression of functional interleukin-3 receptors on Hodgkin and Reed-Sternberg cells.
SO - Am J Pathol 2002 Feb;160(2):585-96
AD - Clinical & Experimental Hematology Research Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Istituto Nazionale Tumori, via Pedemontana Occidentale 12, Aviano I-33081, Italy. firstname.lastname@example.org
The human interleukin-3 receptor (IL-3R) is a heterodimeric complex consisting of an IL-3-specific alpha chain (IL-3Ralpha) and a common beta chain (beta(c)), this latter shared with the receptors for granulocyte-macrophage colony-stimulating factor and IL-5. Despite extensive research on cytokine circuitries regulating proliferation and survival of tumor cells in Hodgkin's disease (HD) the functional expression of IL-3Rs in this pathobiological entity has not yet been investigated. In the present study, we demonstrate that the great majority (>90%) of malignant Hodgkin and Reed-Sternberg cells of classic HD (19 of 19 analyzed cases) express IL-3Ralpha by immunostaining of frozen sections and cell suspensions from involved lymph nodes. Accordingly, HD cell lines (L428, KMH2, HDLM2, L1236) expressed the alpha and beta chains of IL-3R both at the mRNA and protein level, with a molecular size of IL-3Ralpha identical (70 kd) to that expressed by human myeloid cells. Exogenous IL-3 promoted the growth of cultured Hodgkin and Reed-Sternberg cells, such effect being potentiated by IL-9 co-stimulation, and was able to partially rescue tumor cells from apoptosis induced by serum deprivation. This data suggests an involvement of IL-3/IL-3R interactions in the cellular growth of HD through paracrine mechanisms.
UI - 11844834
AU - Weekes CD; Vose JM; Lynch JC; Weisenburger DD; Bierman PJ; Greiner T;
TI - Bociek G; Enke C; Bast M; Chan WC; Armitage JO; Nebraska Lymphoma Study Group Hodgkin's disease in the elderly: improved treatment outcome with a doxorubicin-containing regimen.
SO - J Clin Oncol 2002 Feb 15;20(4):1087-93
AD - University of Nebraska Medical Center, Omaha, NE 68198-7680, USA. email@example.com
PURPOSE: Hodgkin's disease (HD) is a malignancy that displays a bimodal age distribution. Previous reports of treatment in patients greater-than-or-equal 60 years have found a poor outcome, particularly in patients with advanced disease. Because of an improved side-effect profile, the regimen of chlorambucil, vinblastine, procarbazine, and prednisone (ChlVPP) has been proposed for use in elderly patients. previously untreated HD received either ChlVPP (n = 176) or ChlVPP plus doxorubicin/bleomycin/vincristine (ChlVPP/ABV hybrid; n = 86). Fifty-six patients were greater-than-or-equal 60 years old, and 206 were younger than 60 years. RESULTS: The 5-year overall survival (OS; 87% v 39%) and the 5-year event-free survival (EFS; 75% v 31%) favored patients younger than 60 years of age. Prognostic factors analyzed in patients greater-than-or-equal 60 years of age, other than type of therapy, included sex, stage, Karnofsky performance score, lactic dehydrogenase, number of extranodal sites, B symptoms, size of largest mass, and histologic subtype. In patients older than 60 years, none of the clinical features was a statistically significant predictor of EFS; however, ChlVPP/ABV hybrid was associated with a decreased risk of an event (relative risk, 0.40; 95% confidence interval, 0.19 to 0.83; P =.014) compared with ChlVPP. The 5-year OS for patients greater-than-or-equal 60 years who received ChlVPP was 30%, compared with 67% for those patients receiving the ChlVPP/ABV regimen (P =.0086) CONCLUSION: Patients greater-than-or-equal 60 years with HD who require chemotherapy are better treated with ChlVPP/ABV hybrid than with ChlVPP alone.
UI - 11758105
AU - Tez M; Keskek M
TI - Is needle biopsy of the liver necessary in staging laparotomy?
SO - Acta Chir Belg 2001 Sep-Oct;101(5):224-5
AD - Department of General Surgery, Hacettepe University Faculty of Medicine, Ankara 06100, Turkey.
The purpose of this retrospective study was to examine the necessity of needle biopsy in staging laparotomy. Between 1988 and 1998, 31 patients diagnosed with Hodgkin's disease underwent staging laparotomy. All patients had lymph node sampling from perihilar, coeliac, periaortic and iliac regions, splenectomy, wedge biopsy of the liver as well as tru-cut needle biopsies from both liver lobes. Two patients (6.5%) had hepatic involvement of the liver detected by both wedge and needle biopsies. In the remaining patients, all biopsies of the liver obtained by either method were negative. These findings strongly suggest that wedge biopsy of the liver provides sufficient information for the diagnosis and there is no need for tru-cut biopsy which has its own complications.
UI - 11847030
AU - Eghbali H; Soubeyran P; Soubeyran I; Monnerau A; Cazorla S
TI - [Update on lymphomas]
SO - Bull Cancer 2002 Jan;89(1):89-99
AD - Service d'hematologie-oncologie, Institut Bergonie, Centre regional de lutte contre le cancer, 229, cours de l'Argonne, 33076 Bordeaux Cedex.
Important progress have been recently achieved in the management of Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL). Prognostic factors are now better defined in HD thanks to new biologic and radiologic information which complete old and relevant clinical factors. These parameters are expected to improve decision making in patient's management. However, treatment strategy is under new discussion and controversies about the role of radiotherapy and its doses. There are now enough arguments to consider radiotherapy unnecessary in advanced stages when a complete remission is achieved by chemotherapy. There is also important concern about late effects of treatment and not only secondary cancers. Non-Hodgkin's lymphomas are heterogeneous and different entities are now better defined and described, thanks to a common and similar language for immunological clinical data and treatment outcome. New strategies are under investigation using monoclonal antibodies with or without radioisotopes, in association with chemotherapy or radiotherapy. Undoubtedly, these new approaches are going to improve the overall prognosis of NHL.
UI - 11713590
AU - Low SE; Horsman JM; Hancock H; Walters SJ; Hancock BW
TI - Prognostic markers in malignant lymphoma: an analysis of 1,198 patients treated at a single centre.
SO - Int J Oncol 2001 Dec;19(6):1203-9
AD - YCR Department of Clinical Oncology, Weston Park Hospital, Sheffield, UK.
The prognostic significance of 20 putative markers has been assessed in a consecutive series of 1,198 patients with malignant lymphoma seen by the Sheffield Lymphoma Group over three decades. Univariate analysis disclosed that ten factors for both Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) Grade I, and twelve factors for NHL Grade II had prognostic significance. However, multivariate analysis selected only three (age, serum albumin and lymphocyte count) for HD, one (serum albumin) for NHL Grade I and five (age, stage, erythrocyte sedimentation rate, serum albumin and serum lactate dehydrogenase) for NHL Grade II as independent predictors for survival. Risk adjusted prognostic models were derived for Hodgkin's disease and NHL Grade II. For Hodgkin's disease the presence of 3 risk factors predicted for only 35% long-term survival for this group of patients. For NHL Grade II the group with 3-5 risk factors present had a median survival of less than 2 years compared to a 9-year median survival in patients with 1 risk factor present. Whilst these models are being validated on a larger series of patients and will also be tested prospectively, new markers are needed to facilitate decisions on treatment for individual patients.
UI - 11841433
AU - Fend F; Martinez A; Quintanilla-Martinez L; Sanz L; Combalia N; Raffeld
TI - M; Jaffe ES; Montserrat E; Campo E Clonally unrelated Hodgkin's disease following autologous stem cell transplant for B-cell lymphoma.
SO - Br J Haematol 2002 Feb;116(2):329-33
AD - Department of Pathology, Technical University Munich and GSF National Research Center for Environment and Health Neuherberg, Munich, Germany. firstname.lastname@example.org
Lymphoproliferative disorders after autologous stem cell transplantation (SCT) are rare. We describe two cases of Hodgkin's disease (HD) as a late secondary neoplasia following autologous SCT for mantle cell lymphoma and B-cell chronic lymphocytic leukaemia respectively. Both HD cases were of mixed cellularity type, showed Epstein-Barr virus (EBV) positivity and followed an aggressive course. Clonal analysis of rearranged immunoglobulin genes from the primary B-cell neoplasm and the secondary HD provided evidence of separate clonal origins of the two tumours in both patients, thus excluding secondary transformation of the original B-cell clone through EBV as the causative event for development of HD.
UI - 11721380
AU - Yong W
TI - [Trends in the therapy of Hodgkin's disease]
SO - Zhonghua Xue Ye Xue Za Zhi 1999 Nov;20(11):608-9
UI - 11821442
AU - Horning SJ; Hoppe RT; Breslin S; Bartlett NL; Brown BW; Rosenberg SA
TI - Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial.
SO - J Clin Oncol 2002 Feb 1;20(3):630-7
AD - Department of Medicine, Division of Medical Oncology, Stanford University Medical Center, Stanford, CA 94304, USA. email@example.com
PURPOSE: To provide more mature data on the efficacy and complications of a brief, dose-intense chemotherapy regimen plus radiation therapy (RT) to bulky disease sites for locally extensive and advanced-stage Hodgkin's disease. PATIENTS AND METHODS: One hundred forty-two patients with stage III or IV or locally extensive mediastinal stage I or II Hodgkin's disease received Stanford V chemotherapy for 12 weeks followed by 36-Gy RT to initial sites of bulky (> or =5 cm) or macroscopic splenic disease. Freedom from progression (FFP), overall survival (OS), and freedom from second relapse (FF2R) were determined using life-table estimates. Outcomes were analyzed according to the international prognostic score. Late effects of treatment were recorded in follow-up. RESULTS: With a median follow-up of 5.4 years, the 5-year FFP was 89% and the OS was 96%. No patient progressed during treatment, and there were no treatment-related deaths. FFP was significantly superior among patients with a prognostic score of 0 to 2 compared with those with a score of 3 and higher (94% v 75%, P <.0001). No secondary leukemia was observed. To date, there have been 42 pregnancies after treatment. Among 16 patients who relapsed, the FF2R was 69% at 5 years. CONCLUSION: These data confirm our preliminary report that Stanford V chemotherapy with RT to bulky disease sites is highly effective in locally extensive and advanced Hodgkin's disease. It is most important to compare this approach with standard doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy in the ongoing intergroup trial (E2496) to determine whether Stanford V with or without RT represents a therapeutic advance.
UI - 11893364
AU - Wirth A; Seymour JF; Hicks RJ; Ware R; Fisher R; Prince M; MacManus MP;
TI - Ryan G; Januszewicz H; Wolf M Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma.
SO - Am J Med 2002 Mar;112(4):262-8
AD - Division of Radiation Oncology, Peter McCallum Cancer Institute, East Melbourne, Victoria, Australia.
PURPOSE: To compare fluorine-18 fluorodeoxyglucose positron emission tomography (PET) and gallium scanning with each other and with conventional staging, for patients with Hodgkin's disease or non-Hodgkin's lymphoma. SUBJECTS AND METHODS: Fifty patients had PET, gallium scanning, and conventional staging of newly diagnosed or progressive Hodgkin's disease or non-Hodgkin's lymphoma. Disease sites, stage, and treatment plans were assessed retrospectively. RESULTS: Positron emission tomography and gallium scanning each upstaged 14% of patients (n = 7). Management was altered by PET in 9 cases (18%) and by gallium scanning in 7 (14%, P = 0.6). Disease was evident in 117 sites in 42 patients. The case positivity rate for conventional assessment was 90%; for PET, 95%; for gallium scanning, 88%; for conventional assessment plus PET, 100%; and for conventional assessment plus gallium scanning, 98%. Site positivity rates for conventional assessment were 68%; for PET, 82%; for gallium scanning, 69% (conventional vs. PET, P = 0.01; conventional vs. gallium scanning, P = 0.9; PET vs. gallium scanning, P = 0.01); for conventional assessment plus PET, 96%; and for conventional assessment plus gallium scanning, 94%. Positron emission tomography and gallium scanning were entirely concordant in 31 patients; in the other 19 patients, PET identified 25 sites missed by gallium scanning, whereas gallium scanning identified 10 sites missed by PET. CONCLUSION: In this retrospective study, PET demonstrated a higher site positivity rate than did gallium scanning, with similar case positivity rates. These data support the use of PET in place of gallium scanning for the staging of patients with Hodgkin's disease or non-Hodgkin's lymphoma.
The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.
Endocrine System Cancers
Head and Neck Cancers
Urinary Tract Cancers
Bone Marrow Transplants
General Treatment Concerns
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
Cancer Resource List
Resources for Young Adults